December 6, 2017

Farmington's Bioarray gets patent for breast cancer treatment predictive test

Farmington-based molecular diagnostics company Bioarray Genetics Inc. has received a U.S. patent supporting its lead breast cancer predictive test.

The patent covers methods and kits for predicting the effectiveness of breast cancer treatments. The method also generates a report indicating the likelihood of long-term survival with breast cancer recurrence in the patient.

The Bioarray BA100 test will be available to physicians and patients in 2018.

Identifying patient response to a form of therapy at the beginning of the treatment decision-making process can have considerable impact on patient outcomes and health economics, the company said.

"Bioarray's lead test is the first of a pipeline of predictive tests that can provide actionable information to physicians to improve the decision-making process for cancer treatments," said Marcia Fournier, founder and CEO of Bioarray. "The test provides information on treatment response, but is also able to identify those triple negative breast cancer patients with the worst survival rates. This test exemplifies the impact of advanced molecular testing on breast cancer treatment."

Free E-Newsletters

Sign up now for our daily and weekly
e-newsletters! Click Here

Today's Poll Has George Jepsen been a good attorney general for Connecticut?<>
Most Popular on Facebook
Copyright 2017 New England Business Media